According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
HRTX has been the subject of a number of other research reports. Brean Capital initiated coverage on Heron Therapeutics in a research report on Tuesday, October 4th. They issued a buy rating and a $41.00 price target for the company. Lake Street Capital reiterated a buy rating and issued a $45.00 price target on shares of Heron Therapeutics in a research report on Tuesday, September 6th. JMP Securities reiterated a buy rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Jefferies Group decreased their price target on Heron Therapeutics from $46.00 to $40.00 and set a buy rating for the company in a research report on Monday, October 3rd. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $38.00 price target on shares of Heron Therapeutics in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Heron Therapeutics currently has an average rating of Buy and an average target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 17.20 on Wednesday. The company’s 50-day moving average is $18.51 and its 200-day moving average is $18.93. Heron Therapeutics has a 52-week low of $15.13 and a 52-week high of $31.32.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. On average, equities research analysts anticipate that Heron Therapeutics will post ($4.39) earnings per share for the current year.
In other news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now directly owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.31% of the company’s stock.
Several large investors have recently bought and sold shares of HRTX. Nationwide Fund Advisors increased its stake in Heron Therapeutics by 10.2% in the second quarter. Nationwide Fund Advisors now owns 20,730 shares of the biotechnology company’s stock worth $374,000 after buying an additional 1,920 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares during the period. DIAM Co. Ltd. increased its stake in Heron Therapeutics by 7.7% in the second quarter. DIAM Co. Ltd. now owns 300,337 shares of the biotechnology company’s stock worth $5,406,000 after buying an additional 21,473 shares during the period. Emerald Acquisition Ltd. purchased a new stake in Heron Therapeutics during the second quarter worth $451,000. Finally, Swiss National Bank increased its stake in Heron Therapeutics by 3.0% in the second quarter. Swiss National Bank now owns 51,900 shares of the biotechnology company’s stock worth $937,000 after buying an additional 1,500 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.